WO2001076613A1

WO2001076613A1 - Extract for abstaining from narcotics and its preparation

Info

Publication number: WO2001076613A1
Application number: PCT/CN2000/000086
Authority: WO
Inventors: Zhizhong Zuo
Original assignee: Zhizhong Zuo
Priority date: 2000-04-11
Filing date: 2000-04-11
Publication date: 2001-10-18
Also published as: AU2000236545A1

Abstract

An extract is disclosed, the extract can be extracted from the following components: component A is Hominis Placenta. Flower of Datura metel L, toxin of Fugu ocellatus and/or toxin of Naja naja: component B is Root of Panax ginseng, Ginseng Radix Ferum, Ginseng Radix Coreensis and/or Panacis Quinquefolii Radix; component C is Root of Aconitum carmicharli Debx. and/or Skin of Cinnamomum cassia Presl; component D is Herb of Chelidonium majus L; component E is Stem of Corydalis turtschaninovii Bess. f. yuanhusuo Y.H. Chou et c.c. Hsu(yuan hu); component F is Gallstones of Bos taurus domesticus Gmelin and/or Trunk of Dryobalanops aromatica Gaertn. f.; component G is Fruit of Cannabis sativa L. and/or Fruit of Biota orientalis (L) Endl.; component H is Stem of Aipinia officinarum Hance and/or Stem of Zingiber officinale Rosc.; component I is Root of Salvia miltiorrhiza >Bge.; component J is Ziziphus jujuba Mill. and/or Fruit of Ziziphus jujuba Mill. var.inermis(Bge.) Rehd.; component K is Root of Glycyrrhiza uralensis Fish. and/or Honey-Fried Root of Glycyrrhiza uralensis Fish.. The inventive extract has effects including helping narcotic addicts to abstain physiological dependency and psychological dependency, and possesses very low retaking rate, moreover, it can be used to keep calm and ease pain. The invention also provides the preparation of the extract.

Description

Description Detoxification extract and preparation method thereof

The present invention relates to an extract for sedation, analgesia and / or detoxification and a method for preparing the same.

At present, there are two major series of drugs for detoxification: detoxification and detoxification. The alternative is to replace drugs with less addiction with drugs with less addiction in order to reduce the effects of drugs on the nervous system of drug users. For example, the most common drug is methadone, followed by "dihydroetofine hydrochloride "," Dubinofil "," Du Lunding "," Fukang tablets ", etc. The disadvantage is that if these drugs are used for a long time, it is easy to form new drug dependence. Detoxification mainly uses the antagonistic effect of drugs, that is, using one substance to inhibit the effect of another substance on the human body. To reduce drug withdrawal. In this kind of drug treatment, antagonisms often used are cyclazine, naloxone, clonine, and naldrone, which help release toxins accumulated in the body by drug users due to long-term drug use. These drugs can only reduce the withdrawal response and cannot completely eliminate it. Although they do not create new drug dependence, they can cause aversion, sweating, restlessness, and anxiety when initially used. Drugs such as clonidine are short-acting, and abrupt discontinuation after long-term use can produce mild non-opioid withdrawal symptoms. In addition, antagonists only have opioid antagonism, and if they are applied to cocaine addicts, they will cause severe physical impairment.

The above two types of drugs are limited to reducing the physiological response caused by drug withdrawal, but cannot solve the drug hunger of drug users, that is, the above two types of drug treatment are only limited to relieve the physical dependence of drug users and cannot relieve the psychological dependence of drug users. Because drug users' psychological thirst for drugs often exceeds the physical pain caused by quitting drugs, the relapse rate of drug users is extremely high, usually above 90%. Object of the invention

The present invention aims at the shortcomings of the above-mentioned detoxification drugs such as alternatives and detoxification, and provides an extract for sedation, analgesia and / or detoxification. The extract can quit both the physical dependence and the psychological dependence of drug addicts. It is a detoxification extract with a very low relapse rate. At the same time, the extract can also be used for sedation or analgesia. The invention also provides a method for preparing such an extract.

Another object of the present invention is to provide a pharmaceutical composition for use as a sedative, analgesic and / or detoxification drug.

Yet another object of the present invention is to provide a treatment method for analgesia, sedation and / or treatment of drug dependence on physical and psychological dependence of drug users.

Other objects of the present invention are embodied in the detailed description of the present invention. Detailed description of the invention

The inventors have found an extract in long-term research. The extract can not only relieve pain and sedation, but also effectively quit drug addiction.

According to the present invention, an extract is extracted from a composition including the following components in parts by weight:

(1) 45 to 60 parts of component A, which is one or more substances selected from the group consisting of purple river car, daffodil, puffer venom and cobra venom;

(2) 15-30 parts of component B, which is one or more substances selected from ginseng, wild ginseng, Korean ginseng and American ginseng;

(3) 6 to 9 parts of component C is one or more substances selected from aconite and cinnamon; (4) 30 to 60 parts of component D is celandine;

(5) Component E of 9-15 is Yanhusuo (Yuanhu);

(6) 9-15 parts of component F, bezoar; (7) 12-15 parts of component G, which is one or more substances selected from hemp kernels and cypress seeds;

(8) 6 to 12 parts of component H, which is one or more substances selected from galangal and dried ginger;

(9) 15-25 parts of component I is salvia miltiorrhiza;

(10) 15 to 30 parts of component J, which is one or more substances selected from the group consisting of jujube kernel and jujube;

(11) 6-10 parts of component K, which is one or more substances selected from raw licorice and licorice root.

According to the present invention, in the composition for preparing an extract, bezoar of component F can be replaced with or shared with borneol, and the amount of borneol is 0.5-3.0 parts.

In addition to the above components, the composition optionally includes one or more of the following components to enhance the detoxification effect, enhance the patient's ability to resist disease in various organ systems, improve its physiological level, and reduce the drug's toxic side effect. Specifically, in terms of parts by weight, these optional components include:

12-18 copies of blue wind rattan;

12-18 servings of Scutellaria baicalensis;

12-25 copies of Xu Changqing;

9-12 windbreaks;

15-30 servings of astragalus;

9-12 ghost arrow feathers;

12-15 acacia skins;

12-15 servings of ginkgo leaves;

9-12 night vines;

12-15 iris

6-9 servings of toad: 12-25 servings of Happy Bamboo.

According to the invention, a method of sedation, analgesia and detoxification comprises administering to a patient an effective amount of an extract of the invention.

The extract of the present invention may be administered orally, by injection, or the like. Depending on the condition of the patient, the dosage of the extract of the present invention is also different.

When the extract of the present invention is used for sedation, the oral dose for adults is generally 0.3-0.6g each time, 2-3 times a day; the injection dose is generally 0.1-0.3g each time. Increase the dose if necessary.

When the extract of the present invention is used for analgesia, the oral dose for adults is generally 0.6-1.2g each time, and when the pain is taken, the injection dose is generally 0.3-0.6g each time. For patients with advanced cancer and / or severe pain, the dose may be appropriately increased.

When the extract of the present invention is used for detoxification, the dosage to be taken is determined according to factors such as the length of the patient's drug use time, the method of drug use, the type of drug use and other factors. Generally speaking, when administered orally, adults take 1.5-9.0g each time, two to four times a day; when injected, adults take 0.6-3.0g each time, two to four times a day. Because there are many factors that affect the dosage, the patient's condition can be maintained. Based on these dosage ranges, the dosage should be appropriately increased. Specific dosages are as follows:

Table 1

At the time of drug use Mode of drug use Amount of drug A type of drug Oral dose Injectable dose

<3 months suction <0.5g single heroin 1.5-2.4g 0.6-1.2g

<3 months with tin. Foil suction <0.5g Single heroin 1.5-2.4g 0.6-1.2g <3 months injection <0.5g single heroin 3.6-4.8g 1.2-1. 8g

〉 3 months non-injection method <0.5g single heroin 3.6-4.8g 1.2-1.8g

> 3 months injection <0.5g single heroin 3.6-4.8g 1.2- 1.8g

> 3 months non-injection> 0.5g single heroin 4. 5-6. Og 1.5-2.4g

> 3 months injection> 0.5g single heroin 5. 0-9. Og 2. 0-3. Og because the pharmaceutical composition according to the present invention contains an effective amount of the extract of the present invention and a pharmaceutically acceptable carrier And / or excipients. The carriers and / or excipients used are commonly used carriers and / or excipients, such as starch, gelatin and the like.

The pharmaceutical composition of the present invention can be made into various dosage forms, for example, tablets, stomach-soluble, enteric sugar-coated tablets, can be made into powder, granulated or filled into capsules such as stomach-soluble capsules, enteric-coated tablets, The powder can also be soaked in 0.5-2% saline to make an oral solution, and it can also be made into an injection.

The present invention also provides a method for preparing the extract of the present invention, and the preparation method includes the following steps:

(1) Crush the raw materials. The raw materials for preparing the extract of the present invention can be purchased from the market. The pulverization of the raw materials may adopt various conventional methods, such as a grinding method, a liquefaction spiral method, and the like, and a liquefaction spiral method is preferably adopted. The crushed particles of the raw materials are nano-sized, and the particle size is usually between 10 and 300 nanometers, preferably between 10 and 50 nanometers. The 4 bar raw material is broken into 4 nanometer fine powders, which can increase the surface energy of the particles and help improve the extraction rate. Using the liquefaction spiral method, a large amount of lattice distortion can occur inside and on the surface of the particles through high-frequency impact. Defects, increasing the degree of amorphization. (2) The crushed raw materials are extracted with an appropriate amount of water. During water extraction, the amount of water added can be 8 to 12 times the volume of the raw material, preferably 10: 1. The temperature is controlled between 90-100 ° C, and the time for water extraction is generally 90-10 (under TC conditions, lasting 1-2.5 hours, preferably 1.5-2 hours.

(3) The water extract is filtered to obtain a filtrate, and the filtrate is concentrated. The obtained filter residue can be subjected to water extraction again. When water extraction is performed again, the amount of water added is 5-8 times the volume of the raw material. The water extraction step can be performed multiple times, preferably twice.

(4) Add 70% ethanol to the concentrate and place it in a water bath at 80-85 ° C for reflux. The ratio of the amount of ethanol added to the volume of the concentrate is 1.5-2.5: 1, preferably 1.5: 1. The time is generally 20-60 minutes, preferably 30-45 minutes. After refluxing, the concentrated solution is allowed to stand for a period of 2-3 hours.

(5) The treatment solution after standing is filtered to obtain a filtrate, and then the filtrate is concentrated. The concentrated solution can be further processed as required. For example, the concentrate is dried to obtain a powder. For drying, conventional drying methods are used, for example, spray drying, vacuum freeze drying, and the like. According to the method of the present invention, the filtration can adopt a conventional filtration method, such as a centrifugal filtration method and the like. Concentration can be condensed using a conventional vacuum film evaporator and centrifugal thin film.

Certain raw materials such as cinnamon and dried ginger used to prepare the extract of the present invention contain some volatile oils such as cinnamon oil and gingerol. When the extract of the present invention is stored for a long period of time, these volatile oils will gradually volatilize, affecting the medicinal effect of the extract of the present invention. In order to increase the shelf life of the extract of the present invention, the raw materials such as cinnamon and dried ginger may be pre-treated before the raw material pulverization step to stabilize the volatile oil contained in the raw materials.

In the pretreatment step, the raw materials such as cinnamon and ginger are distilled by the conventional distillation and steaming method, the temperature is controlled in the range of 90-120 ° C, and the distillation time is in the range of 10-30 minutes. The distilled raw material is sent to a pulverization step, and the volatile oil that has been distilled off is stabilized with β-cyclodextrin, and then subjected to water extraction together with the pulverized fine powder. The concentrate is usually concentrated to 20-50% of the filtrate volume, and then dried. When spray drying is used, the actual temperature of droplet drying during the drying process is only 35-50 ° C, which is completed in a few seconds or ten seconds. Generally, the concentrated liquid's inlet air temperature is 110-130 ° C, and the outlet air temperature is 65-80 ° C. Add this powder to 0.9% saline to make a good mouth liquid.

In a vacuum freeze-drying method, the concentrated liquid is treated at about -50 ° C and a pressure of 0.1 OlKpa, and a dry powder containing about 3% water can be obtained. After 30 minutes of UV disinfection, the capsules were filled.

The filtrate can also be concentrated into a paste, diluted with an appropriate amount of water, refrigerated for 24 hours, filtered, and added with a single syrup, potassium citrate, volatile oil, and an appropriate amount of water to 1000 ml, refrigerated, filtered, and sealed in 10 ml It is obtained by sterilizing in an ampoule for 30 minutes at 100 ° C.

The extract of the present invention can be used for sedation, analgesia and detoxification. When the extract of the present invention is used as a detoxification drug, it has very prominent advantages compared with the detoxification drugs in the prior art.

(1) It can improve the microcirculation of the whole body, especially the microcirculation in the brain area, and effectively promote the production of endogenous morphinin in the brain, thereby achieving the subjective fight against the temptation of drugs.

(2) Inhibition of d ₂ receptor activity in the brain can significantly alleviate and eliminate the symptoms of opiates (morphine, heroin, durodin) and drug addicts such as cocaine, marijuana and methamphetamine.

(3) Adjusting the balance of the mediators in the brain cells helps to adjust the autonomic dysfunction caused by drugs, that is, the sequelae of "think addiction" and "relapse".

(4) Yiyangyang, qi-eliminating phlegm, clearing the phlegm, detoxifying and analgesic, refreshing the brain and soothe the nerves, clearing the mind and annoying, refreshing the spleen and resuscitating, strengthening the spleen and kidney, nourishing and strengthening, and adjusting the balance of human function.

Due to the above-mentioned outstanding advantages, the detoxification effect of the extract of the present invention is very obvious:

1. Significant detoxification effect, no toxic side effects and adverse reactions, and a wide range of applications (applicable to morphine, heroin, durodin, cocaine, marijuana and ice addicts>.

2. Fast onset, short treatment period, 3-7 days can relieve physical dependence, namely drug addiction, 7-20 days But ^ "anti-psychological dependence, that is, heart addiction.

3. No euphoria, no addiction.

4. High withdrawal rate and low relapse rate. Heineken test

As a result of the acute toxicity test performed with the extract of the present invention, the mouse has a lethal dose of LD ₅ . It is 4. 86 + 0. 58g / kg.

The long-term toxicological test performed with the extract of the present invention shows that the extract of the present invention is free of teratogenic, carcinogenic, mutagenic and visceral function damage. Animal test-risk of curative effect of extract of the present invention

A pure microcirculation model related to drug addiction suppression was established in Wister purebred rats. The brain was decapitated for brainstem, hypothalamus, and striatum. LEK) radioimmunoassay. The results showed that the MEK and LEK contents of the three brain regions of drug-addicted rats were lower than those of normal rats, with significant differences except for the brainstem MEK. The MEK and LEK in the three brain regions of the group taking the detoxification extract of the present invention, except for the brainstem MEK, all returned to the enkephalin value of normal constitution rats. before. Clinical trial of the extract of the invention

432 patients with heroin detoxification syndrome were treated with the extract of the present invention, and the effect was satisfactory by comparison with other drug control groups.

All cases in this trial conform to the classification and diagnosis guidance for the use of psychoactive drugs in mental and behavioral disorders in the International Classification of Diseases (ICD-10) and the American College of Psychiatry's Systematic Manual for the Diagnosis of Mental Illness (the second revised edition) ) (DSMI II-R) Diagnostic criteria for substance abuse and drug dependence-related disorders.

Treatment group 432 cases: 270 males and 162 females. Aged 12 to 67 years, with an average age of 23 years, with a course of January to 10 years, with an average of 36.8 months, of which 38 cases were within March and 42 were from March to June. In June, there were 54 cases in 1 year, 236 cases in 1 to 5 years, and 62 cases in more than 5 years; 372 cases of heroin alone; 26 cases of heroin and marijuana; 25 cases of heroin, etofi, and dulentin 9 cases of heroin and ecstasy; 132 cases of smokers; 264 cases of injectors; 36 cases of inhalers and injectors; 180 cases of 0.5 g or less; 192 cases of 0.5 -1 g or more; 1 g or more There were 60 cases; except for 6 cases which were treated for the first time, all others had undergone detoxification methods such as compulsory method, hibernation method, methadone, Young's +1, buprenorphine, one case for 31 cases, and two cases for 64 cases. There were 43 cases with 3 times, 57 cases with 4 times, and 231 cases with 5 times or more.

The control group consisted of 175 patients, 105 males and 70 females, aged 15-39 years, with an average age of 26 years, with a course of March to 7 years, with an average of 33. June. There were 13 cases from March to June, 47 cases from June to 1 year, 90 cases from 1 to 5 years, and 25 cases from more than 5 years; 95 cases were treated with heroin alone; 32 cases were treated with heroin and marijuana; heroin, Etofi 41 cases were shared by Du Leng Ding; 7 cases were heroin and Ecstasy: 85 cases were ingested; 73 cases were injected; 17 cases were shared by inhalation and injection; 17 cases were ingested under 0.5 g, 0.5-1 g were ingested 93 cases, 65 cases with 1 gram or more, except for 17 cases which were treated for the first time, the rest have undergone detoxification methods such as compulsory method, hibernation method, methadone, Young's 1 + 1, etc., 39 cases in one case, and 18 cases in 2 cases There were 29 cases with 3 times, 63 cases with 4 times, and 26 cases with 5 times or more.

Randomized controlled trials are divided into three major groups, each of which includes a treatment group and a control group. A group of 30 patients were randomly assigned to the treatment group according to 2: 1, and 65 patients in the control group; 170 patients in the treatment group were randomly assigned to 2.5: 1, and 68 patients in the control group; C group was randomly assigned to 85 in the 2: 1 treatment group. There were 42 cases in the control group and 47 cases without a control group.

treatment method

(1) Direct withdrawal Table 2

Seven days after taking the extract of the present invention, a small amount of sedative hypnotics is assisted. After taking the extract of the present invention, patients no longer use drugs and morphine anesthetics, and patients with particularly severe symptoms are treated symptomatically with non-narcotic drugs.

table 3

(2) Reduced withdrawal method

Patients can continue to take drugs at the same time (including the treatment group and the control group) using the detoxification drugs. The drugs used can be used to reduce the amount of drug use. Medication will gradually reduce the amount of drug use until withdrawal, the course of treatment is about 2-3 months. Observation method

Patients in each treatment group and control group recorded changes in symptoms and signs

Efficacy standards refer to the Himme sbach withdrawal symptoms scoring system.

-Cure: Withdrawal symptoms no longer occur or the intramuscular injection of naloxone 0.4 to 0.8 mg does not occur after the patient stops using all drugs (physical symptoms disappear, psychological dependence disappears). -Significant: Patients withdraw all symptoms within 3 months after withdrawal of all drugs or intramuscular injection of naloxone 0.4-0.8 mg, some physical symptoms, most psychological dependence.

-Improvement: The patient may still experience partial withdrawal symptoms or intramuscular injection of naloxone 0.4 to 0.8 mg after the withdrawal of all medications, and most of the physical symptoms and psychological dependence may occur.

-Ineffective: No change in physical symptoms, patients still dependent on drugs, and withdrawal symptoms after intramuscular injection of naloxone.

The test results are listed in Table 4 below:

Table 4

Healing markedly improved ineffective cure rate total effective

(Example) (example) (example) (example) (%) (%)

Group A:

Treatment group (130 87 32 11 0 67. 2 100 patients)

Control group (65 23 23 14 5 35. 3 92 patients)

Group B

Treatment group (170 106 47 15 2 62. 6 98. 7 cases)

Control group (68 29 18 19 3 42. 3 95. 2 cases)

Group C

Treatment group (85 51 19 12 3 60. 4 96. 8 cases)

Control group (42 16 11 12 38. 5 92. 1 cases)

ί Direct abstinence was used in 387 patients, all of whom were completely free of addiction, with a cure rate of 100%, and a follow-up of 3 to 24 months. The relapse rate was 1.3%.

Patients who use the reduced-dose withdrawal method complain that the use of the extract of the present invention before taking or injecting drugs is both boring and painful, and the brain is painful. During the taking of the extract of the present invention, the drug consumption is reduced by 70- 80%, the mental state is obviously improved. If you increase the amount of drug use, you will have dizziness, nausea and even vomiting.

Forty-five patients who used this method had no painful withdrawal after taking the extract of the present invention for 2 months.

The present invention will be further described below with reference to specific examples of the extract of the present invention. It should be understood that these examples are not intended to limit the protection scope of the present invention. In these examples, the various ingredients in the extract are in parts by weight unless otherwise stated. Examples 1-4

In these examples, the extracts of the present invention are prepared according to the amounts of various raw material ingredients listed in Table 5 (in the table in grams) according to the method described below, and the specific content of the preparation method is as follows:

The required amount of the raw materials was pulverized into a slurry-like fine powder by a liquefaction spiral method, and the average particle diameter of the fine powder was 50 nm. The crushing equipment used is DRS-2 (produced by Jiangsu Superfine Powder Engineering Technology Research Center). Water was added to the fine powder and extracted at 100 ° C. The volume ratio of water to fine powder was 10: 1. The obtained extract was filtered to obtain a filtrate. The obtained residue was subjected to water extraction again, and then filtered. The first water extraction took 2 hours and the second water extraction took 1.5 hours. The volume ratio of water to fine powder during the second water extraction was 7: 1. The two filtrates were combined and concentrated. After cooling, 70% ethanol was added to the concentrated solution. After refluxing in a water bath at 80-85 ° C for 30 minutes, it was left for 24 hours and then filtered. The amount of ethanol added was the volume of the concentrated solution. 1. 5 times. The filtered filtrate was concentrated to contain 30 total alkaloids per milliliter of the concentrate. The extraction solution was filtered, separated by a common centrifuge, the residue was removed, and then a high-speed centrifuge (1.4 (10,000-16,000 rpm) centrifugation. The concentrated liquid is spray-dried to obtain a powdery extract of the present invention.

table 5

Number Composition Example 1 Example 2 Example 3 Example 4

1 Purple River Car 60 30 50 60

Ginseng 15 15

2 Wild ginseng 18

Korean Ginseng

American Ginseng 30

3 cinnamon 6 8 6

Aconite 9

4 Celandine 30 60 50 60

5 Yanhusuo 15 9 12 15

(Yuanhu)

6 Bezoar 15 9 12 15

7 Boziren 15

Hemp seeds 15 12 15

8 Galangal 9

Dried ginger 6 9 6

9 Salvia 25 15 20 25

10 jujubes 30

Jujube kernel 15 20 15

11 Licorice 6

Raw Licorice 10 9 10

12 Blue Wind Rattan 12 15 18 13 Yellow tea 12 15 18

14 Xu Changqing 12 20 15

15 Windproof 12 10 9

16 Astragalus 15 20 30

17 Ghost Arrow Feather 9 10 12

18 acacia leather 12 12 15

19 Ginkgo biloba 12 15 15

20 Yejiao 12 10 9

21 Iris calamus 12 15 15 Example 5

The method for preparing the extract of the present invention in this embodiment is the same as that in Examples 1 to 4, but the composition of the composition used for extraction is 45 g of purple river car, 25 g of ginseng, 9 g of cinnamon, 45 g of celandine, 15 g of Yanhusuo (yuanhu) , Qingfengteng 15g, bezoar 10g, hemp kernel 15g, Xiaoyao bamboo 15g, dried ginger 9g, salvia 20g, jujube kernel 20g, toad 9g, acacia peel 15g, astragalus 25g, ginkgo leaf 15g, stone calamus 12g, water flakes 2g, windproof 9g, and licorice 6g. Example 6

The method for preparing the extract of the present invention in this embodiment is the same as that in Examples 1 to 4, but the composition of the composition for extraction is 45g of golden lily, 15g of Korean ginseng, 6g of cinnamon, 6g of aconite, 30g of celandine, blue wind Rattan 16g, hemp kernel 15g, bezoar 10g, salvia 15g, dried ginger 6g, jujube kernel 15g, raw licorice 6g, Yanhusuo (Yuanhu) 12g, stone calamus 12g, astragalus 20g, windproof 9g, Xu Changqing 20g. Based on the content of the invention, changes can be made to the present invention, for example, the detoxification extract of the present invention can be made into different dosage forms for convenient taking and carrying, or the detoxification extract of the present invention is added with a drug Some auxiliary components, such as perfumes, toners, and the like, which are well known in the physical field, belong to the spirit of the present invention, and they should be regarded as falling within the protection scope determined by the claims attached to the present invention.

Claims

Claim

An extract for sedation, analgesia and / or detoxification, which is extracted from a composition containing the following components, and by weight parts, these components are:

(2) 15 to 30 parts of component B, which is one or more substances selected from ginseng, wild mountain ginseng, Korean ginseng and American ginseng;

(3) 6-9 parts of component (:, is one or more substances selected from aconite and cinnamon of devolatile oil;

(4) 30-60 parts of component D is celandine;

(5) Component E of 9-15 is Yanhusuo (Yuanhu);

(6) component F, which is 9-15 parts of bezoar and / or 0.5-3.0 parts of water flakes;

(7) 12 to 15 parts of component G, which is one or more substances selected from hemp kernels and cypress seeds;

(8) 6-12 parts of component H, which is one or more substances selected from the group consisting of galangal and devolatile dried ginger;

(9) 15-25 parts of component I is salvia miltiorrhiza;

(11) 6 to 10 parts of component K, which is one or more substances selected from raw licorice and licorice root.

2. The extract of claim 1, wherein the composition further contains one or more substances selected from the group consisting of:

12-18 Blue Wind Vine: 12-18 servings of Scutellaria baicalensis;

12-25 copies of Xu Changqing;

9-12 windbreaks;

15-30 servings of astragalus;

9-12 ghost arrow feathers;

12-15 acacia skins;

12-15 servings of ginkgo leaves;

9-12 night vines;

12-15 iris

6-9 toads;

12-25 servings of Happy Bamboo.

3. A pharmaceutical composition comprising an effective amount of the extract of claim 1 or 2 and a pharmaceutically acceptable excipient or carrier.

4. A pharmaceutical composition according to claim 3 for detoxification, sedation and Z or analgesia.

5. A method of detoxification, sedation and / or analgesia, comprising administering to a patient an effective amount of the extract of claim 1 or 1.

6. The method of claim 5, wherein the oral dose for an adult for detoxification is 1.5-9. Og / times, 2 to 4 times per day.

7. The method of claim 5, wherein the injection dose for adults for detoxification is 0.6-3. Og / times, 2 to 4 times a day.

8. A method for preparing the extract of claim 1 or 2, comprising the steps of:

(1) crush the raw materials to a particle size of about 10-300 nm,

(2) extract the crushed raw materials with an appropriate amount of water, and the extraction temperature is about 90-100 ° C,

(3) the filtrate after the water extract is concentrated for the first time,

(4) after the concentrated solution is subjected to reflux treatment with 70% ethanol, and then allowed to stand, One

(5) After filtering the treatment solution after standing, the filtrate is concentrated for the second time.

The method according to claim 8, wherein the filter residue obtained in step (3) is subjected to a second water extraction.

10. The method according to claim 8 or 9, wherein the pulverization uses a liquefaction spiral method.